Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.

Rebecca C Arend David M O'Malley Susana BanerjeeKimmie McLaurinRichard DavidsonGráinne H Long

Published in: Advances in therapy (2021)

Differences between the licensed PARPi were observed in the risk of experiencing a CEI, likelihood of dose modifications, ability to receive continuous PARPi therapy, HCRU, and costs.

Keyphrases

healthcare
health insurance
electronic health record
big data
stem cells
structural basis
machine learning
mesenchymal stem cells
health information
social media
data analysis
bone marrow